Clinical Trials Logo

FGFR1 Gene Amplification clinical trials

View clinical trials related to FGFR1 Gene Amplification.

Filter by:
  • None
  • Page 1

NCT ID: NCT04096417 Active, not recruiting - Clinical trials for Stage IV Colorectal Cancer AJCC v8

Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations

Start date: August 31, 2020
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well pemigatinib works in treating patients with colorectal cancer with mutations (alterations) in a FGFR gene and that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Pemigatinib may stop the growth of tumor cells by blocking FGFR, which is needed for cell growth.

NCT ID: NCT02965378 Completed - Clinical trials for Recurrent Squamous Cell Lung Carcinoma

Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Start date: October 2014
Phase: Phase 2/Phase 3
Study type: Interventional

This phase II/III trial studies how well FGFR inhibitor AZD4547 (AZD4547) works in treating patients with stage IV squamous cell lung cancer that has come back after previous treatment. This is a sub-study that includes all screened patients positive for the fibroblast growth factor receptor (FGFR) biomarker. FGFR can cause tumor cells to grow more quickly. AZD4547 may decrease the activity of FGFR and may be able to shrink tumors.

NCT ID: NCT02706691 Terminated - Clinical trials for Head and Neck Squamous Cell Carcinoma

BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer

Start date: June 1, 2018
Phase: Phase 2
Study type: Interventional

This phase IIa trial studies how well the experimental drug, BGJ398 (infigratinib), works in treating patients with fibroblast growth factor receptor (FGFR) 1-3 translocated, mutated, or amplified head and neck cancer that has returned after a period of improvement. BGJ398 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.